Pazopanib

Results: 16



#Item
1SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

Add to Reading List

Source URL: www.gov.pe.ca

Language: English - Date: 2015-04-28 07:44:05
2landmarks Report from CAGMO Renal cell carcinoma Is Pazopanib the Preferred First-line Treatment for Metastatic Renal Cell Carcinoma? Eric Winquist, MD, FRCPC, FACP, Consultant Medical Oncologist, London Health Sciences

landmarks Report from CAGMO Renal cell carcinoma Is Pazopanib the Preferred First-line Treatment for Metastatic Renal Cell Carcinoma? Eric Winquist, MD, FRCPC, FACP, Consultant Medical Oncologist, London Health Sciences

Add to Reading List

Source URL: www.oncologyex.com

- Date: 2013-11-09 15:26:22
    3#514: Phase I Study of Pazopanib in Combination with the Investigational Hypoxia-targeted Drug TH-302 Kellen L. Meadows, Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. Georg

    #514: Phase I Study of Pazopanib in Combination with the Investigational Hypoxia-targeted Drug TH-302 Kellen L. Meadows, Paula H. Lee, Richard F. Riedel, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. Georg

    Add to Reading List

    Source URL: www.thresholdpharm.com

    Language: English - Date: 2013-11-26 16:23:25
      4Votrient® (pazopanib) Core communications

      Votrient® (pazopanib) Core communications

      Add to Reading List

      Source URL: www.euikcs.com

      Language: English - Date: 2014-05-13 15:03:58
      5Mesothelioma Articles - Clinical Trial : Pazopanib in Treatin...

      Mesothelioma Articles - Clinical Trial : Pazopanib in Treatin...

      Add to Reading List

      Source URL: www.mirg.org

      Language: English - Date: 2010-10-19 13:01:02
      6Microsoft Word[removed]Pazopanib VOTRIENT GSK[removed]PSD FINAL.doc

      Microsoft Word[removed]Pazopanib VOTRIENT GSK[removed]PSD FINAL.doc

      Add to Reading List

      Source URL: www.pbs.gov.au

      Language: English - Date: 2015-03-06 00:23:42
      7Votrient® (pazopanib) for Kidney Cancer Votrient is a medication used to treat advanced kidney cancer in adults. Dosage: 800mg once a day How supplied: 200mg tablets Storage: Room temperature. Route of Administration: V

      Votrient® (pazopanib) for Kidney Cancer Votrient is a medication used to treat advanced kidney cancer in adults. Dosage: 800mg once a day How supplied: 200mg tablets Storage: Room temperature. Route of Administration: V

      Add to Reading List

      Source URL: dev66.geckodesigns.com

      Language: English - Date: 2014-10-30 16:15:10
      8ODAC Pediatric Subcommittee November 1, 2011 Development of Votrient™ (Pazopanib) in Pediatric Oncology

      ODAC Pediatric Subcommittee November 1, 2011 Development of Votrient™ (Pazopanib) in Pediatric Oncology

      Add to Reading List

      Source URL: www.fda.gov

      Language: English
      9Selected Phase I Clinical Trials (Updated May[removed]Compound Target

      Selected Phase I Clinical Trials (Updated May[removed]Compound Target

      Add to Reading List

      Source URL: www.accrf.org

      Language: English - Date: 2014-05-08 11:32:12
      10Votrient® (pazopanib) for Kidney Cancer Votrient is a medication used to treat advanced kidney cancer in adults. Dosage: 800mg once a day How supplied: 200mg tablets Storage: Room temperature. Route of Administration: V

      Votrient® (pazopanib) for Kidney Cancer Votrient is a medication used to treat advanced kidney cancer in adults. Dosage: 800mg once a day How supplied: 200mg tablets Storage: Room temperature. Route of Administration: V

      Add to Reading List

      Source URL: www.kidneycancer.org

      Language: English - Date: 2014-01-19 16:05:29